Dr. Brander on the Treatment Landscape for Patients With High-Risk CLL

Danielle M. Brander, MD
Published: Friday, Jul 20, 2018



Danielle Marie Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the treatment landscape for patients with high-risk chronic lymphocytic leukemia (CLL).

High-risk patients with CLL have benefitted from recent novel therapies, says Brander, but their prognosis is still concerning. As a result of these novel therapies, patients are grateful that they do not have to receive chemotherapy, particularly if they are TP53 dysfunctional.

However, there is a subset of patients who are intolerant to the newer agents. Additionally, resistance poses an issue for a lot of patients, especially for those who develop resistance to ibrutinib (Imbruvica). In recent studies, patients who stopped or progressed on ibrutinib went to venetoclax (Venclexta) and showed greater than 60% response rates. However, physicians know that the patients who never experience a deep response eventually relapse.

Additionally, physicians are struggling to make recommendations for patients who develop acquired resistance to more than one novel agent. In those cases, Brander suggests other consolidation options such as allogeneic stem cell transplant. It is an area of need that may one day be met with chimeric antigen receptor T-cell therapy or immunotherapy, she says.


Danielle Marie Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the treatment landscape for patients with high-risk chronic lymphocytic leukemia (CLL).

High-risk patients with CLL have benefitted from recent novel therapies, says Brander, but their prognosis is still concerning. As a result of these novel therapies, patients are grateful that they do not have to receive chemotherapy, particularly if they are TP53 dysfunctional.

However, there is a subset of patients who are intolerant to the newer agents. Additionally, resistance poses an issue for a lot of patients, especially for those who develop resistance to ibrutinib (Imbruvica). In recent studies, patients who stopped or progressed on ibrutinib went to venetoclax (Venclexta) and showed greater than 60% response rates. However, physicians know that the patients who never experience a deep response eventually relapse.

Additionally, physicians are struggling to make recommendations for patients who develop acquired resistance to more than one novel agent. In those cases, Brander suggests other consolidation options such as allogeneic stem cell transplant. It is an area of need that may one day be met with chimeric antigen receptor T-cell therapy or immunotherapy, she says.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x